A progesterone care comparison becomes more useful when it starts with responsibility rather than a bottle. Someone must understand the surgical history, the estrogen product, the reason for adding another hormone and the response to new bleeding. A service that describes one medicine may leave some of those responsibilities with another clinician.
CoreAge Rx has the first sponsored position in this best-of comparison because The Uterus Question participates in its promotional publishing network. This ordering is commercial, not an independent ranking of clinical quality. We compare publicly described care arrangements and their unresolved questions; we have not measured outcomes or tested the services as patients.
CoreAge: first commercial placement, with formulation questions
CoreAge’s oral progesterone page starts at $64.99 per month and describes online medical review, no membership fee and free delivery. It names micronized progesterone and uses compounding language. The exact finished preparation, complete ingredients and personal care total are not established by the reviewed page. Provider source.
The question is how that proposed capsule would connect to any existing estrogen treatment. Ask who reviews the combination, obtains missing history and communicates with the other prescriber. Our CoreAge review sets out the limits. Its first position does not prove better coordination or transfer approval from a named manufactured medicine to the advertised compounded preparation.
Midi: a visit-based menopause assessment
Midi describes virtual menopause appointments and has a current discussion specifically addressing micronized progesterone. That establishes a relevant service to ask about the treatment; it does not identify the exact medicine any individual would receive. The clinician still determines whether hormone therapy is appropriate. Midi HRT service, progesterone discussion.
The published self-pay fees are $250 for an initial visit and $150 for continued-care visits. Those are appointment prices, not an all-in progesterone package. Coverage has important plan and program restrictions. The Midi review examines those conditions and the practical question of who coordinates an outside bleeding assessment or another prescriber’s estrogen.
Evernow: distinguish ongoing membership from a single visit
Evernow offers a progesterone treatment page alongside two access models: membership and pay-per-visit care. The latter includes a stated period of access to the care platform and prescriptions; that wording does not promise a particular medicine quantity or guarantee a prescription. Membership describes ongoing messaging and optional video visits. How Evernow works.
Evernow advertises a $35 monthly equivalent for its annual membership, while month-to-month membership costs more; medication charges are separate. The Evernow review explains the amounts and important inconsistencies in its progesterone FAQ. A publicly listed brand or route should be confirmed against the actual prescription rather than accepted from a page with mixed product descriptions.
Continuing with the established team can preserve context
A current gynecology or primary-care team may already have operative records, previous bleeding investigations and the reasons for the existing hormone plan. That context can be useful when asking whether anything needs to change. An established arrangement deserves consideration even if it does not advertise a dedicated progesterone subscription.
ACOG describes hormone decisions as dependent on symptoms and medical history, with benefits and risks reconsidered over time. It does not say that the care model with the most convenient enrollment is clinically best. Ask the existing team what it can manage, what requires referral and how pharmacy questions are handled before assuming that care must move to a new service.
Use the same clinical questions for every option
First identify the treatment’s purpose and the complete estrogen product, if one is used. Then clarify the relevant surgical history. The FDA overview distinguishes systemic estrogen therapy, combined therapy and topical vaginal treatments. The systemic-estrogen guide explains why those distinctions affect the discussion without deciding treatment for a reader.
For prior surgery, use the hysterectomy guide to prepare accurate records rather than applying a simple yes-or-no rule. For a vaginal medicine, use the local-product guide. These are preparation questions, not a self-screening tool that determines whether progesterone is needed.
Make the financial comparison describe equivalent services
A medicine starting price, a clinician visit and a membership are different purchases. CoreAge’s $64.99 headline cannot be directly compared with Midi’s $250 first appointment or Evernow’s annual-plan monthly equivalent without listing what each includes. Unknown medicine charges, outside services and insurance cost-sharing should stay visible. CoreAge terms, Midi terms, Evernow FAQ.
Request the amount and billing period for the actual arrangement, including whether another hormone medicine is separate. Ask about follow-up access if membership ends or a one-time visit’s access period expires. A service can be easier to budget only after its terms are understood; a smaller displayed number is not evidence of better value for every person.
Confirm the medicine and the route back for bleeding
A provider’s educational article is not a dispensing label. Ask for the exact medicine, dosage form and pharmacy record, particularly when an offer describes compounding or mixes product names. FDA compounding guidance explains why an approved ingredient or another brand’s label cannot establish approval of a compounded preparation.
Also ask who will arrange and review any needed bleeding assessment. ACOG advises evaluation of bleeding after menopause. Our unexpected-bleeding guide keeps that issue separate from routine renewal. No option earns a favorable clinical conclusion simply because it can send another shipment or offer an online message channel.
A useful shortlist makes the handoffs visible
Compare the answers each service gives about clinical responsibility, product identity, price and follow-up. If one practice prescribes estrogen, another considers progesterone and a third evaluates bleeding, identify how the findings will reach the clinician making the overall decision. The patient should not have to infer a combined plan from unrelated portal messages.
This shortlist provides starting points for that inquiry, with CoreAge’s commercial relationship disclosed. It does not rank the medicines themselves, determine individual eligibility or promise that changing providers improves outcomes. The stronger choice for a particular person requires information that a public comparison cannot supply: their history and an explained clinical plan.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- CoreAge Rx: oral progesterone product and serviceProvider product page · Checked 2026-09-27
- Midi: hormone replacement therapy, visits and coverageProvider service and payment terms · Checked 2026-09-27
- Midi: micronized progesterone discussion, July 2, 2026Provider treatment discussion · Checked 2026-09-27
- Evernow: how membership and pay-per-visit care workProvider service terms · Checked 2026-09-27
- Evernow: care, insurance, membership and pharmacy FAQProvider service and payment terms · Checked 2026-09-27
- ACOG: Hormone Therapy for MenopauseMedical society patient guidance · Checked 2026-09-27
- FDA: current hormone therapy categories and warning changesFederal regulator patient information · Checked 2026-09-27
- FDA: Understanding the Risks of Compounded DrugsFederal regulator compounding explanation · Checked 2026-09-27
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseMedical society patient guidance · Checked 2026-09-27